Patent application number | Description | Published |
20080249070 | Cycloalkane-Containing Sphingosine 1-Phospate Agonists - The present invention provides sphingosine-1-phosphate analogs that are potent, and selective agonists at one or more S1P receptors, specifically the S1P | 10-09-2008 |
20080312160 | METHOD OF TREATING ENTERITIS, INTESTINAL DAMAGE, AND DIARRHEA FROM C. DIFFICILE WITH AN A2A ADENOSINE RECEPTOR AGONIST - A therapeutic method for treating intestinal damage, enteritis, diarrhea, or a combination thereof caused by a | 12-18-2008 |
20080318901 | Novel Lysophosphatidic Acid Receptor Selective Antagonists - The present invention is directed to compositions comprising lysophosphatidic acid analogs and methods of using such analogs as agonist or antagonists of LPA receptor activity. In addition the invention is directed to LPA receptor agonists that vary in the degree of selectivity at individual LPA receptors (i.e. LPA1, LPA2 and LPA3). More particularly the present invention is directed to LPA analogs wherein the glycerol is replaced with ethanolamine and a variety of substitutions have been linked at the second carbon atom. | 12-25-2008 |
20090042955 | BICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS - Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors. | 02-12-2009 |
20090062238 | METHOD FOR TREATMENT OF NEUROPATHIC PAIN - Compounds and methods useful for preventing and treating pain, e.g., neuropathic pain, in a subject in need thereof are provided. The compounds can be “S1P modulating” agents that are capable of inducing a detectable change in S1P receptor activity. | 03-05-2009 |
20090105315 | PHENYL-CYCLOALKYL AND PHENYL-HETEROCYCLIC DERIVATIVES AS S1P RECEPTOR AGONISTS - Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors. | 04-23-2009 |
20090137531 | Aryl Amide Sphingosine 1- - The present invention provides compounds that have antagonist activity at the S1P | 05-28-2009 |
20090170803 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES - The present invention provides a therapeutic method for treating biological diseases that includes the administration of an effective amount of a suitable antibiotic agent, antifungal agent or antiviral agent in conjunction with an A | 07-02-2009 |
20090197835 | VINYL PHOSPHONATE LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS - The present invention provides LPA analogs that are antagonists at the LPA receptors. | 08-06-2009 |
20090234019 | T Type Calcium Channel Inhibitors - The present invention provides novel T type calcium channel inhibitors of formula (I), the use thereof in the treatment of a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, | 09-17-2009 |
20090253647 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY - The invention provides compounds having the following general formula (I): | 10-08-2009 |
20090253759 | TETRALIN ANALOGS HAVING SPHINGOSINE 1-PHOSPHATE AGONIST ACTIVITY - Tetralin analogs that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs, which, after phosphorylation, can behave as agonists at S1P receptors. | 10-08-2009 |
20090253760 | HYDRINDANE ANALOGS HAVING SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONIST ACTIVITY - Hydrindane analogs that have agonist activity at one or more of the S | 10-08-2009 |
20090253761 | BENZOCYCLOHEPTYL ANALOGS HAVING SPHINGOSINE 1-PHOSPHATE RECEPTOR ACTIVITY - Benzocycloheptyl analogs that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs, which, after phosphorylation, can behave as agonists at S1P receptors. | 10-08-2009 |
20090298788 | 2-POLYCYCLIC PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY - The invention provides compounds having the following general formula (I): | 12-03-2009 |
20100016258 | PHOSPHONATE DERIVATIVES AS AUTOTAXIN INHIBITORS - The present invention provides β-hydroxy phosphonate compounds that are autotaxin inhibitors. | 01-21-2010 |
20100105690 | LISOFYLLINE ANALOGS AND METHODS FOR USE - Analogs of a Lisofylline (LSF), and synthetic methods for the preparation of such analogs are provided. The analogs of LSF provided have the ability to protect cell viability, particularly the ability to protect pancreatic β-cells. | 04-29-2010 |
20100152127 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF - The invention provides compounds having the following general formula (I): | 06-17-2010 |
20100240617 | BICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS - Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors. | 09-23-2010 |
20100249074 | BENZYL-CYCLOALKYL SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATORS - Sphingosine- | 09-30-2010 |
20110106241 | COMPOSITIONS AND METHODS FOR INHIBITING SPHINGOSINE KINASE - Amidine analogs that can inhibit the activity of sphingosine kinase 1 and sphingosine kinase 2 (SphK1 & SphK2) are provided. The compounds can prevent angiogenesis in tumor cells. | 05-05-2011 |
20110136755 | 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY - The invention provides compounds having the following general formula (I): | 06-09-2011 |
20110195936 | BICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS - Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors. | 08-11-2011 |
20110245204 | CYCLOALKANE-CONTAINING SPHINGOSINE 1-PHOSPHATE AGONISTS - The present invention provides sphingosine-1-phosphate analogs that are potent, and selective agonists at one or more S1P receptors, specifically the S1P | 10-06-2011 |
20120010187 | BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS - The invention provides FIG. | 01-12-2012 |
20120214858 | IMIDAMIDE SPHINGOSINE KINASE INHIBITORS - Imidamide (amidine) analogs that can inhibit the activity of sphingosine kinase 1 and sphingosine kinase 2 (SphK1 & SphK2) are provided. The compounds can prevent angiogenesis in tumors. | 08-23-2012 |
20130084313 | SUPPLEMENT FOR OSTOMY PATIENTS - The present application describes a supplement containing an enteric coated alpha-D-galactosidse and the use thereof to treat an ostomy patient. | 04-04-2013 |
20130137693 | LISOFYLLINE ANALOGS AND METHODS FOR USE - Analogs of a Lisofylline (LSF), and synthetic methods for the preparation of such analogs are provided. The analogs of LSF provided have the ability to protect cell viability, particularly the ability to protect pancreatic β-cells. | 05-30-2013 |
20130317070 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS - The invention provides for the use of antimicrobial chemical entities based on a nitrothiazolide backbone that exhibit anti-mycobacteria activity, including the mycobacterium causing tuberculosis. Multiple compounds were synthesized and screened for anti-tuberculosis activity. Disclosed herein are a series of compounds with anti-tuberculosis activity, including six leads that completely inhibited bacterial growth at 5 micrograms per ml or less. Three of these compounds were tested to determine MIC and these ranged between 1 and 4 micrograms per ml against both drug susceptible | 11-28-2013 |
20140018355 | LISOFYLLINE ANALOGS AND METHODS FOR USE - The present invention provides analogs of a Lysofylline (LSF), and synthetic methods for the preparation of such analogs. The have the active side chain moiety (5-R-hydroxyhexyl) of LSF and can have greater potency and oral bioavailability than LSF. | 01-16-2014 |
20150018330 | BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS - The invention provides novel antimicrobial chemical entities based on a nitrothiazolide backbone that exhibit antibacterial and antiparasitic action against a wide range of human pathogens. The new classes of compounds show extended action against Gram positive bacteria including MRSA drug resistant pathogens. In the Gram-positive organisms, they specifically target and functionally inhibit microbial attachment to surfaces and biofilm formation. In Gram-negative bacteria, including enteroaggregative | 01-15-2015 |